Targeted Agents in AML (ABT199)

被引：0
|
作者：
Konopleva, Marina [1 ]
DiNardo, Courtney [1 ]
Pan, Rongqing Aaron [1 ]
Han, Lina [1 ]
Zhang, Qi [1 ]
Daver, Naval [1 ]
Kantarjian, Hagop [1 ]
Andreeff, Michael [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd 10, Houston, TX 77030 USA
来源：
ANNALS OF HEMATOLOGY | 2017年 / 96卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S28 / S29
页数：2
相关论文
共 50 条
  • [1] Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199
    Naqvi, Kiran
    Konopleva, Marina
    Ravandi, Farhad
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (10) : 863 - 874
  • [2] ABT199 and ONC201 in Diffuse Large B Cell Lymphoma Cell Lines
    Khan, Nadia
    Zhou, Lanlan
    Babar, Jawad
    Allen, Joshua
    Fisher, Richard I.
    Eldeiry, Wafik S.
    BLOOD, 2015, 126 (23)
  • [3] Combined treatment of ABT199 and irinotecan suppresses KRAS-mutant lung cancer cells
    Xu, Yinhai
    Zong, Shuai
    Gao, Xin
    Zhang, Haoliang
    Wang, Bin
    Li, Pengpeng
    Liu, Tielong
    Li, Shibao
    GENE, 2019, 688 : 1 - 6
  • [4] Genetic Characterization of ABT-199 Sensitivity in Human AML
    Bordeleau, Marie-Eve
    Bisaillon, Richard
    Thiollier, Clarisse
    Krosl, Jana
    Lehnertz, Bernhard
    Lavallee, Vincent-Philippe
    MacRae, Tara
    Caroline, Labelle
    Boucher, Genevieve
    Boivin, Isabel
    D'Angelo, Giovanni
    Lavallee, Sylvie
    Marinier, Anne
    Lemieux, Sebastien
    Hebert, Josee
    Sauvageau, Guy
    BLOOD, 2018, 132
  • [5] Genetic characterization of ABT-199 sensitivity in human AML
    Richard Bisaillon
    Céline Moison
    Clarisse Thiollier
    Jana Krosl
    Marie-Eve Bordeleau
    Bernhard Lehnertz
    Vincent-Philippe Lavallée
    Tara MacRae
    Nadine Mayotte
    Caroline Labelle
    Geneviève Boucher
    Jean-François Spinella
    Isabel Boivin
    Giovanni D’Angelo
    Sylvie Lavallée
    Anne Marinier
    Sébastien Lemieux
    Josée Hébert
    Guy Sauvageau
    Leukemia, 2020, 34 : 63 - 74
  • [6] Genetic characterization of ABT-199 sensitivity in human AML
    Bisaillon, Richard
    Moison, Celine
    Thiollier, Clarisse
    Krosl, Jana
    Bordeleau, Marie-Eve
    Lehnertz, Bernhard
    Lavallee, Vincent-Philippe
    MacRae, Tara
    Mayotte, Nadine
    Labelle, Caroline
    Boucher, Genevieve
    Spinella, Jean-Francois
    Boivin, Isabel
    D'Angelo, Giovanni
    Lavallee, Sylvie
    Marinier, Anne
    Lemieux, Sebastien
    Hebert, Josee
    Sauvageau, Guy
    LEUKEMIA, 2020, 34 (01) : 63 - 74
  • [7] Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199
    Shihui Mao
    Qing Ling
    Jiajia Pan
    Fenglin Li
    Shujuan Huang
    Wenle Ye
    Wenwen Wei
    Xiangjie Lin
    Yu Qian
    Yungui Wang
    Xin Huang
    Jiansong Huang
    Jinghan Wang
    Jie Jin
    Journal of Translational Medicine, 19
  • [8] Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199
    Mao, Shihui
    Ling, Qing
    Pan, Jiajia
    Li, Fenglin
    Huang, Shujuan
    Ye, Wenle
    Wei, Wenwen
    Lin, Xiangjie
    Qian, Yu
    Wang, Yungui
    Huang, Xin
    Huang, Jiansong
    Wang, Jinghan
    Jin, Jie
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [9] MCL-1 inhibition improves ABT199 efficacy for BCL-2-dependent neuroblastoma
    Bate-Eya, Laurel T.
    den Hartog, Ilona J. M.
    van der Ploeg, Ida
    Schild, Linda
    Koster, Jan
    Versteeg, Rogier
    Caron, Huib N.
    Molenaar, Jan J.
    Dolman, M. Emmy M.
    CANCER RESEARCH, 2016, 76
  • [10] The 3-Drug Combination Treatment ART838, ABT199 Plus Sorafenib Is Effective Against AML Xenografts, Possibly Via Cooperative Targeting of MCL1
    Moses, Blake S.
    Fox, Jennifer
    Chen, Xiaochun
    McCullough, Samantha
    Sang Ngoc Tran
    Kirkpatrick, Allison
    Kumar, Kalyani
    Tyner, Jeffrey W.
    Posner, Gary H.
    Civin, Curt I.
    BLOOD, 2018, 132
12345